Mesoblast Limited (MEOBF)
| Previous Close | 0.6051 |
| Open | 0.5500 |
| Bid | 0.0000 x 0 |
| Ask | 0.0000 x 0 |
| Day's Range | 0.6051 - 0.6051 |
| 52 Week Range | 0.1000 - 1.0000 |
| Volume | |
| Avg. Volume | 82,066 |
| Market Cap | 690.244M |
| Beta (5Y Monthly) | 2.59 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.0900 |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
Simply Wall St.Three Leading Growth Companies In Australia With Insider Ownership Reaching 27%
As the Australian market navigates through fluctuating bond yields and anticipates potential interest rate hikes, investors are closely monitoring various economic indicators and corporate activities. Amid these conditions, companies with high insider ownership can be particularly intriguing, as such ownership might align management's interests more closely with those of shareholders, potentially fostering greater resilience and long-term strategic focus during uncertain times.
ZacksMesoblast (MESO) to File Pediatric GVHD Drug BLA, Stock Up
Mesoblast (MESO) gains as the FDA states that the available phase III data for lead candidate, remestemcel-L, is sufficient to support a regulatory filing for pediatric SR-aGVHD indication.
GlobeNewswireUnited States Food & Drug Administration (FDA) Notifies Mesoblast that Available Clinical Data from Phase 3 Trial Appear Sufficient to Support BLA Submission for Remestemcel-L in Children with Steroid-Refractory Acute Graft Versus Host Disease (SR-aGVHD)
NEW YORK, March 25, 2024 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced that U.S. FDA has informed the company that following additional consideration the available clinical data from its Phase 3 study MSB-GVHD001 appears sufficient to support submission of the proposed Biologics License Application (BLA) for remestemcel-L for treatment of pediatric patients with steroid-refractory acute graf
